ibrutinib treatment for cll yields different pfs in population-based setting
Published 6 years ago • 254 plays • Length 1:07Download video MP4
Download video MP3
Similar videos
-
0:58
ibrutinib for cll within a population-based setting: a promising outlook
-
2:38
ibrutinib treatment for cll does not increase the incidence of richter’s transformation
-
6:05
real-world data on the effect of ibrutinib flexible dosing treatment strategies on ttnt in cll/sll
-
1:56
ibrutinib plus venetoclax for first-line treatment of cll: 4-year follow-up data
-
1:38
front-line use of ibrutinib for cll in a real-world setting
-
3:11
btk inhibitors for cll: acalabrutinib vs ibrutinib
-
2:14
targeting b-cell receptor signaling for anticancer therapy
-
2:51
genetic markers in patients with early-stage cll treated with ibrutinib: findings from cll12
-
2:39
the safety and efficacy of ibrutinib for the treatment of cll
-
2:06
the role of ibrutinib in the frontline treatment of young patients with cll
-
2:43
outcomes in high-risk cll patients following fixed-duration treatment with ibrutinib plus venetoclax
-
1:56
ibrutinib treatment and its associated risk factors
-
3:46
the characteristics and mode of action of ibrutinib for cll
-
4:08
phase ib trial of ianalumab plus ibrutinib for cll
-
2:45
optimizing the combination of ibrutinib plus venetoclax in cll
-
2:56
resonate-2: ibrutinib and chlorambucil for frontline cll
-
1:09
ibrutinib combination therapy in cll: overview of the data so far
-
1:47
ianalumab add-on therapy in cll patients receiving ibrutinib
-
2:14
positive results for captivate: ibrutinib and venetoclax for cll
-
2:07
efficacy of ibrutinib in the treatment of cll patients with del(17p) and tp53 mutation
-
3:48
ibrutinib in treatment for refractory or relapsed cll
-
1:56
emerging ibrutinib-based combinations in cll